Are Psychedelics the Key to Living Forever? (ft. Bryan Johnson)

What It Covers

Bryan Johnson documents his 5-MeO-DMT experience as a structured longevity experiment, comparing its neurological effects to psilocybin trials he previously conducted. He presents preliminary data on brain rejuvenation, default mode network disruption, and metabolic reset, while discussing upcoming therapies including mitochondrial transplantation and personalized organoids.

Key Questions Answered

• •Psychedelic Dosing Protocol: Johnson administered 9mg intramuscular followed by 18mg vaporized 5-MeO-DMT under supervised, quantified conditions — not recreational settings. He argues that most adverse outcomes from psychedelics stem from unknown mushroom strains, unmeasured psilocybin doses, and unsupervised environments, making structured clinical protocols the critical variable separating therapeutic benefit from psychological harm.
• •Default Mode Network Reset: 5-MeO-DMT completely disrupts the default mode network — the brain system responsible for ego, rumination, and self-referential thought. Using Kernel's optical brain interface, Johnson previously documented that psilocybin at 25mg clinical doses visibly scrambled neural traffic patterns, generating new connectivity. He describes 5-MeO-DMT as producing a far more complete shutdown than psilocybin.
• •Psilocybin Metabolic Data: Three 25mg psilocybin doses produced a measurable metabolic reset in Johnson's body, moving his blood glucose from the 99.5th to the 99.9th population percentile — a shift he describes as extremely difficult to achieve through conventional interventions. The protocol also altered his microbiome composition, suggesting systemic effects beyond neurological changes alone.
• •Mitochondrial Transplantation Pipeline: Johnson is pursuing mitochondrial therapy through a phase-two company within weeks. The strategy involves drawing blood from a maternally-related young donor — whose mitochondria are genetically matched — culturing those mitochondria externally, then reintroducing them. He suggests sprint performance testing as a practical biomarker to measure functional improvement beyond standard blood panels.
• •Personalized Organoid Testing: Johnson has converted his own blood cells into induced pluripotent stem cells, then differentiated them into heart, liver, and lung tissue organoids. This system allows candidate drugs and compounds to be tested on his own tissue in a dish before human administration, compressing the trial-and-error timeline and enabling combinatorial dosing experiments without direct personal risk.